June 03, 2013

LONDON (Reuters) Jun 03 - GlaxoSmithKline said on Monday that its breast cancer drug lapatinib in combination with chemotherapy did not improve survival rates for patients with gastric cancer compared to the use of chemotherapy alone.

Lapatinib, which is marketed as Tykerb mainly in the U.S. and as Tyverb mainly in Europe, is approved for the treatment of breast cancer and some other solid tumors.

At the annual meeting of the American Society of Clinical Oncology, the British company said the drug did not meet the primary end point of improving overall survival rates for patients with HER2-positive advanced gastric cancer, including esophageal, in a late-stage global trial.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.
Post as: